Developing a new medicine is a long, expensive, and uncertain process. Scientists may need to study thousands of molecules before finding a promising candidate, and even then, most potential medicines do not make it through clinical development.

Artificial intelligence is changing parts of this process.

AI can analyze huge biological datasets, identify potential drug targets, predict molecular properties, search for promising compounds, and help researchers design clinical trials. In 2026, researchers are also experimenting with AI systems that connect many of these tasks into larger research workflows.

But AI is not a shortcut around biology. Every promising prediction still needs scientific and clinical validation.

How AI Is Used in Drug Discovery

Traditional drug discovery involves many stages, from understanding a disease and identifying a biological target to finding molecules that affect that target and testing their safety and effectiveness.

AI can assist at several points.

Finding Potential Drug Targets

Researchers can use machine learning to analyze genomic, protein, medical-record, and other biological datasets to identify relationships that might point toward useful drug targets.

Target identification is important because choosing the wrong biological target can lead to years of research without producing an effective medicine. A 2026 Nature Reviews Drug Discovery review describes AI as increasingly useful for target identification and assessment, while emphasizing that target validation remains difficult.

AI can therefore help researchers narrow enormous biological search spaces and identify candidates for further investigation.

Predicting Which Molecules Might Work

Once researchers have a potential target, they need to find molecules that interact with it in useful ways.

AI models can learn from existing chemical and biological data to predict properties such as molecular activity, binding behavior, toxicity, and other characteristics.

Instead of experimentally testing every possible molecule, researchers can use AI to prioritize candidates for laboratory experiments.

A 2026 study in Nature Machine Intelligence demonstrated a machine-learning approach designed to identify molecules outside the chemical space represented in its training data. The researchers experimentally validated seven compounds with low-micromolar activity against two clinically relevant kinases.

This illustrates an important role for AI: helping scientists decide which experiments are worth performing next.

AI and Protein Research

Proteins play central roles in almost every biological process, making them important targets for drug research.

AI-based protein models can help researchers predict structures, interactions, and other molecular properties. These predictions can provide useful starting points for understanding disease mechanisms and designing potential treatments.

However, a predicted structure or molecular interaction is still a scientific hypothesis. Laboratory experiments are needed to determine whether the prediction holds up in reality.

AI Can Analyze Clinical Data

AI is also moving beyond early-stage discovery.

Clinical research generates enormous quantities of information, including patient characteristics, laboratory measurements, imaging data, treatment outcomes, and safety signals.

Machine learning can help researchers organize and analyze these datasets.

AI can potentially assist with identifying suitable patients, matching patients with clinical trials, monitoring data, and detecting patterns that might otherwise be difficult to recognize.

A 2026 Nature Reviews Bioengineering review describes AI-enabled clinical-trial approaches involving patient-to-trial matching, data monitoring, digital twins, prognostic prediction, and automated data curation. The researchers emphasize that these systems need fit-for-purpose validation and human oversight before being used in consequential settings.

Real-Time Clinical Research Is Developing

Another interesting development is the use of AI and data science to make clinical trials more responsive.

In 2026, the U.S. FDA announced proof-of-concept real-time clinical trials in which safety signals and trial endpoints can be shared with the agency as studies progress. The initiative is exploring whether faster access to validated trial information can improve monitoring and decision-making.

AI is not responsible for every part of this process, but advances in AI and data science are helping make continuous analysis of clinical information increasingly practical.

AI Agents Are Beginning to Connect the Pieces

Perhaps the most exciting development is the emergence of systems that use multiple AI agents to perform different research tasks.

In September 2026, Nature reported research on a system called Virtual Biotech, which used as many as 37,000 AI agents to analyze data from more than 55,000 clinical trials and investigate potential therapeutic targets. In one demonstration, the system identified CD276 as a potential target for lung cancer and proposed a possible antibody-drug strategy.

This is an impressive research demonstration, but an important distinction matters: the reported predictions have not yet been validated through clinical trials.

The system shows what AI-assisted drug research could look like, rather than proving that AI can independently develop successful medicines.

What Are the Benefits?

AI could potentially improve drug research in several ways.

Faster Data Analysis

Computers can process enormous datasets much faster than researchers can manually examine them.

Better Candidate Selection

AI can help scientists prioritize molecules and experiments, potentially reducing unnecessary laboratory work.

Exploring More Possibilities

Machine learning can search chemical and biological spaces containing far more possibilities than researchers could realistically test one by one.

Supporting Clinical Trials

AI may help with patient matching, data monitoring, trial design, and analysis.

Identifying New Connections

AI can combine information from different sources and identify relationships that researchers may want to investigate experimentally.

AI Still Has Major Limitations

Despite the excitement, AI has not solved the fundamental difficulty of drug development.

A major 2026 Nature Reviews Drug Discovery assessment concluded that evidence for clinically meaningful impact from AI in drug discovery remains limited. Many AI-driven programs are still in preclinical development, and demonstrating that AI actually improves clinical outcomes remains challenging.

One problem is data quality.

AI systems learn from available information, and biological data can be incomplete, noisy, inconsistent, or difficult to compare across experiments.

Another problem is generalization. A model can perform well on familiar molecules but struggle when presented with chemically or biologically unusual examples. Recent research specifically highlights this challenge in molecular machine learning.

There is also the problem of false confidence. An AI-generated prediction can sound convincing while being incorrect.

Safety Must Come First

Drug development involves human lives, so accuracy alone is not enough.

The FDA's January 2026 guidance on good AI practice in drug development emphasizes human-centered design, risk-based validation, defined contexts of use, appropriate standards, and oversight. It also stresses that medicines must continue to meet requirements for quality, efficacy, and safety.

This means AI should support scientific decision-making without bypassing the evidence required to demonstrate that a medicine is safe and effective.

The Future of AI-Powered Drug Discovery

The future could involve increasingly connected AI systems.

An AI platform might analyze disease biology, identify a target, design potential molecules, predict their properties, select candidates for laboratory testing, interpret experimental results, and suggest the next round of experiments.

Robotic laboratories could then perform many of those experiments automatically.

The goal would not simply be to make computers generate more drug candidates. The real goal is to create a faster learning cycle between AI predictions and physical experiments.

If researchers can improve that cycle while maintaining rigorous validation, AI could become an increasingly important part of medical research.

Conclusion

Artificial intelligence is transforming drug discovery by giving researchers new ways to analyze biological data, identify potential targets, predict molecular properties, prioritize drug candidates, and improve parts of clinical research.

Some of the most interesting developments are happening now, including AI systems that combine literature analysis, biological data, clinical-trial information, and hypothesis generation.

But the science remains grounded in experimentation.

AI can suggest a molecule. A laboratory must test it.

AI can predict a treatment effect. Clinical research must evaluate it.

AI can identify a promising target. Researchers must determine whether changing that target actually helps patients.

The future of AI in medicine is therefore not about replacing scientists. It is about giving scientists better tools to explore biology, test ideas, and make informed decisions faster—while safety, evidence, and human oversight remain essential.

Frequently Asked Questions

How is AI used in drug discovery?

AI can analyze biological and chemical data, identify potential drug targets, predict molecular properties, prioritize compounds, and help researchers design experiments and clinical studies.

Can AI create new medicines?

AI can help design or identify promising drug candidates, but an AI-generated candidate is only the beginning. Laboratory studies, clinical trials, manufacturing controls, and regulatory evaluation are still required.

Can AI make clinical trials faster?

AI can potentially help with patient selection, trial matching, data monitoring, and analysis. Researchers are also exploring real-time clinical-trial approaches, but these systems require careful validation before widespread adoption.

What is the biggest limitation of AI drug discovery?

One major limitation is that strong performance in computational testing does not necessarily translate into successful clinical outcomes. Data quality, generalization, biological complexity, validation, and clinical translation remain significant challenges.

Will AI replace pharmaceutical researchers?

Current evidence supports AI as an increasingly powerful research tool rather than a replacement for scientists. Human researchers remain essential for experimental validation, interpretation, safety decisions, clinical judgment, and regulatory oversight.